Comment
doi: 10.1016/j.jclinepi.2021.12.020.
Epub 2021 Dec 16.
Missing trials from regulatory document of methylphenidate for adults with attention-deficit/hyperactivity disorder: Response to Boesen et al
Affiliations
- PMID: 34923025
- DOI: 10.1016/j.jclinepi.2021.12.020
Item in Clipboard
Comment
Missing trials from regulatory document of methylphenidate for adults with attention-deficit/hyperactivity disorder: Response to Boesen et al
J Clin Epidemiol.
2022 May.
No abstract available
Comment in
-
Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: A case study of public documents: author's reply.J Clin Epidemiol. 2022 May;145:183-184. doi: 10.1016/j.jclinepi.2021.12.021. Epub 2021 Dec 20. J Clin Epidemiol. 2022. PMID: 34936911 No abstract available.
Comment on
-
Missing trials in drug regulatory dossiers may have good reasons, but should be predefined and transparent.J Clin Epidemiol. 2022 Feb;142:258-260. doi: 10.1016/j.jclinepi.2021.10.026. Epub 2021 Nov 5. J Clin Epidemiol. 2022. PMID: 34748906 No abstract available.
-
Clinical trials were missing from regulatory documents of extended-release methylphenidate for ADHD in adults: a case study of public documents.J Clin Epidemiol. 2022 Mar;143:242-253. doi: 10.1016/j.jclinepi.2021.10.027. Epub 2021 Nov 6. J Clin Epidemiol. 2022. PMID: 34752938
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
